Evaluating an ER Degrader for Breast Cancer

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2015-068
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Moesin Is an Independent Prognostic Marker for ER‑positive Breast Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Gene Expression-Based Predictive Markers for Paclitaxel Treatment in ER+ and ER− Breast Cancer

Frontiers in Genetics
GeneticsMolecular Medicine
2019English

First-Line Abemaciclib Effective in ER+ Breast Cancer

Cancer Discovery
Oncology
2017English

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

Genetically Engineered ER -Positive Breast Cancer Mouse Models

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2014English

Pictilisib Plus Anastrozole Reduces Proliferation in ER+ Breast Cancer

Cancer Discovery
Oncology
2016English

AKT1 - A New Marker for Tamoxifen Resistance in ER-Dependent Breast Cancer

2004English

A 16 Yin Yang Gene Expression Ratio Signature for ER+/node− Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

ER-α36-Mediated Rapid Estrogen Signaling Positively Regulates ER-Positive Breast Cancer Stem/Progenitor Cells

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy